Glaukos Co. (NYSE:GKOS) Receives $151.08 Average Price Target from Analysts

Glaukos Co. (NYSE:GKOS) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $151.08.

GKOS has been the topic of several recent analyst reports. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Stephens raised Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. boosted their price target on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. UBS Group assumed coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. Finally, Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th.

Insider Activity

In related news, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at $4,859,454.08. This represents a 23.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 15,328 shares of company stock worth $2,289,521. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Glaukos

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. William Blair Investment Management LLC acquired a new position in Glaukos in the 4th quarter worth about $121,390,000. Alliancebernstein L.P. increased its holdings in Glaukos by 1,235.4% in the 4th quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier’s stock worth $122,374,000 after purchasing an additional 755,035 shares in the last quarter. Norges Bank acquired a new position in Glaukos in the 4th quarter worth about $84,490,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Glaukos by 47.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock worth $83,609,000 after purchasing an additional 207,338 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Trading Up 4.6 %

NYSE GKOS opened at $153.06 on Thursday. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of -50.68 and a beta of 1.04. The stock’s 50 day moving average price is $151.66 and its two-hundred day moving average price is $138.22. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a 52 week low of $83.90 and a 52 week high of $163.71.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.